Demographic, clinical and laboratory characteristics of rapidly progressive glomerulonephritis in Turkey: Turkish Society of Nephrology-Glomerular Diseases (TSN-GOLD) Working Group.
Anti-glomerular basement membrane antibody
Anti-neutrophil cytoplasmic antibody
Immune complex glomerulonephritis
Rapidly progressive glomerulonephritis
Journal
Clinical and experimental nephrology
ISSN: 1437-7799
Titre abrégé: Clin Exp Nephrol
Pays: Japan
ID NLM: 9709923
Informations de publication
Date de publication:
Feb 2021
Feb 2021
Historique:
received:
02
04
2020
accepted:
29
09
2020
pubmed:
12
10
2020
medline:
3
11
2021
entrez:
11
10
2020
Statut:
ppublish
Résumé
In our study, diagnostic and demographic characteristics of patients diagnosed with RPGN by biopsy, clinical and laboratory findings in our country were investigated. Data were obtained from the Turkish Society of Nephrology Glomerular Diseases (TSN-GOLD) Working Group database. Demographic characteristics, indications for biopsy, diagnosis of the glomerular diseases, comorbidities, laboratory and biopsy findings of all patients were recorded. According to their types, RPGN patients were classified as type 1 (anti-GBM related), type 2 (immuncomplex related) and type 3 (pauci-immune). Of 3875 patients, 200 patients with RPGN (mean age 47.9 ± 16.7 years) were included in the study which constitutes 5.2% of the total glomerulonephritis database. Renal biopsy was performed in 147 (73.5%) patients due to nephritic syndrome. ANCA positivity was found in 121 (60.5%) patients. Type 1 RPGN was detected in 11 (5.5%), type 2 RPGN in 42 (21%) and type 3 RPGN in 147 (73.5%) patients. Median serum creatinine was 3.4 (1.9-5.7) mg/dl, glomerular filtration rate was 18 (10-37) ml/min/1.73m Our data are generally compatible with the literature. Advanced chronic histopathological findings were prominent in the biopsy of 21 patients. Early biopsy should be performed to confirm the diagnosis of RPGN and to avoid unnecessary intensive immunosuppressive therapy. In addition to the treatments applied, detailed data, including patient and renal survival, are needed.
Sections du résumé
BACKGROUND
BACKGROUND
In our study, diagnostic and demographic characteristics of patients diagnosed with RPGN by biopsy, clinical and laboratory findings in our country were investigated.
METHODS
METHODS
Data were obtained from the Turkish Society of Nephrology Glomerular Diseases (TSN-GOLD) Working Group database. Demographic characteristics, indications for biopsy, diagnosis of the glomerular diseases, comorbidities, laboratory and biopsy findings of all patients were recorded. According to their types, RPGN patients were classified as type 1 (anti-GBM related), type 2 (immuncomplex related) and type 3 (pauci-immune).
RESULTS
RESULTS
Of 3875 patients, 200 patients with RPGN (mean age 47.9 ± 16.7 years) were included in the study which constitutes 5.2% of the total glomerulonephritis database. Renal biopsy was performed in 147 (73.5%) patients due to nephritic syndrome. ANCA positivity was found in 121 (60.5%) patients. Type 1 RPGN was detected in 11 (5.5%), type 2 RPGN in 42 (21%) and type 3 RPGN in 147 (73.5%) patients. Median serum creatinine was 3.4 (1.9-5.7) mg/dl, glomerular filtration rate was 18 (10-37) ml/min/1.73m
CONCLUSIONS
CONCLUSIONS
Our data are generally compatible with the literature. Advanced chronic histopathological findings were prominent in the biopsy of 21 patients. Early biopsy should be performed to confirm the diagnosis of RPGN and to avoid unnecessary intensive immunosuppressive therapy. In addition to the treatments applied, detailed data, including patient and renal survival, are needed.
Identifiants
pubmed: 33040246
doi: 10.1007/s10157-020-01978-6
pii: 10.1007/s10157-020-01978-6
doi:
Substances chimiques
Antibodies, Antineutrophil Cytoplasmic
0
Creatinine
AYI8EX34EU
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
173-183Références
Greenhall GH, Salama AD. What is new in the management of rapidly progressive glomerulonephritis? Clin Kidney J. 2015;8:143–50. https://doi.org/10.1093/ckj/sfv008 .
doi: 10.1093/ckj/sfv008
pubmed: 25815169
pmcid: 4370308
Kantauskaite M, Laucyte-Cibulskiene A, Miglinas M. Histopathological classification-A prognostic tool for rapidly progressive glomerulonephritis. Medicina (Kaunas). 2018. https://doi.org/10.3390/medicina54020017 .
doi: 10.3390/medicina54020017
Wu T, Peng J, Meng T, Liu Q, Ao X, Lin W, Yin H, Chen J, Pu J, Peng Z, Peng W, Li X, Xiao X, Zhou Q, Zhong Y, Xiao P. Clinicopathological features and prognostic analysis of 49 cases with crescentic glomerulonephritis. Exp Ther Med. 2019;18:3984–90. https://doi.org/10.3892/etm.2019.8023 .
doi: 10.3892/etm.2019.8023
pubmed: 31611938
pmcid: 6781789
Jennette JC, Thomas DB. Crescentic glomerulonephritis. Nephrol Dial Transplant. 2001;16:80–2.
doi: 10.1093/ndt/16.suppl_6.80
Baldwin DS, Neugarten J, Feiner HD, Gluck M, Spinowitz B. The existence of a protracted course in crescentic glomerulonephritis. Kidney Int. 1987;31:790–4. https://doi.org/10.1038/ki.1987.67 .
doi: 10.1038/ki.1987.67
pubmed: 3553703
Couser WG. Rapidly progressive glomerulonephritis: classification, pathogenetic mechanisms, and therapy. Am J Kidney Dis. 1988;11:449–64. https://doi.org/10.1016/s0272-6386(88)80079-9 .
doi: 10.1016/s0272-6386(88)80079-9
pubmed: 3287904
Wall N, Harper L. Complications of long-term therapy for ANCA-associated systemic vasculitis. Nat Rev Nephrol. 2012;8:523–32. https://doi.org/10.1038/nrneph.2012.107 .
doi: 10.1038/nrneph.2012.107
pubmed: 22664736
de Joode AA, Sanders JS, Stegeman CA. Renal survival in proteinase 3 and myeloperoxidase ANCA-associated systemic vasculitis. Clin J Am Soc Nephrol. 2013;8:1709–17. https://doi.org/10.2215/CJN.01020113 .
doi: 10.2215/CJN.01020113
pubmed: 23846462
pmcid: 3789333
Ozturk S, Sumnu A, Seyahi N, Gullulu M, Sipahioglu M, Artan S, Bicik Z, Kutlay S, Keles M, Oygar D, Odabas AR, Kayatas M, Dursun B, Sayarlioglu H, Trablus S, Taymez DG, Ozdemir AA, Sahin GM, Altun B, Azak A, Altintepe L, Suleymanlar G, Koc M, Selcuk Y, Kazancioglu R, Erkoc R, Gursu M, Kucuk M, Akcaoglu SA, Yıldız A, Unal A, Akarsu O, Ates K, Cankaya E, Turkmen A. Demographic and clinical characteristics of primary glomerular diseases in Turkey. Int Urol Nephrol. 2014;46:2347–55. https://doi.org/10.1007/s11255-014-0838-3 .
doi: 10.1007/s11255-014-0838-3
pubmed: 25269407
Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J; CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) (2009) A new equation to estimate glomerular filtration rate. Ann Intern Med 150:604–12. https://doi.org/10.7326/0003-4819-150-9-200905050-00006
Can O, Gumrukcu G, Vardar Aker F, Guren AK, Bilek G, Apaydin S, Manga SG. Rapidly pregressive glomerulonephritis: a single-center experiences. Turk Nephrol Dial Transpl. 2018;27:249–53. https://doi.org/10.5262/tndt.2018.3131 .
doi: 10.5262/tndt.2018.3131
Tang Z, Wu Y, Wang Q, Zeng C, Yao X, Hu W, Chen H, Liu Z, Li L. Clinical spectrum of diffuse crescentic glomerulonephritis in Chinese patients. Chin Med J (Engl). 2003;116:1737–40.
Andrassy K, Kuster S, Waldherr R, Ritz E. Rapidly progressive glomerulonephritis: analysis of prevalence and clinical course. Nephron. 1991;59:206–12. https://doi.org/10.1159/000186552 .
doi: 10.1159/000186552
pubmed: 1956482
Jennette JC. Rapidly progressive crescentic glomerulonephritis. Kidney Int. 2003;63:1164–77. https://doi.org/10.1046/j.1523-1755.2003.00843.x .
doi: 10.1046/j.1523-1755.2003.00843.x
pubmed: 12631105
Chen S, Tang Z, Xiang H, Li X, Chen H, Zhang H, Hu W, Zeng C, Liu Z. Etiology and outcome of crescentic glomerulonephritis from a single center in china: a 10-year review. Am J Kidney Dis. 2016;67:376–83. https://doi.org/10.1053/j.ajkd.2015.07.034 .
doi: 10.1053/j.ajkd.2015.07.034
pubmed: 26388283
Chen M, Cui Z, Zhao MH. ANCA-associated vasculitis and anti-GBM disease: the experience in China. Nephrol Dial Transplant. 2010;25:2062–5. https://doi.org/10.1093/ndt/gfq134 .
doi: 10.1093/ndt/gfq134
pubmed: 20228070
Arimura Y, Muso E, Fujimoto S, Hasegawa M, Kaname S, Usui J, Ihara T, Kobayashi M, Itabashi M, Kitagawa K, Hirahashi J, Kimura K, Matsuo S. Evidence-based clinical practice guidelines for rapidly progressive glomerulonephritis 2014. Clin Exp Nephrol. 2016;20(3):322–41. https://doi.org/10.1007/s10157-015-1218-8 .
doi: 10.1007/s10157-015-1218-8
pubmed: 27099135
pmcid: 4891375
Gupta R, Singh L, Sharma A, Bagga A, Agarwal SK, Dinda AK. Crescentic glomerulonephritis: a clinical and histomorphological analysis of 46 cases. Indian J Pathol Microbiol. 2011;54:497–500. https://doi.org/10.4103/0377-4929.85081 .
doi: 10.4103/0377-4929.85081
pubmed: 21934209
Vizjak A, Rott T, Koselj-Kajtna M, Rozman B, Kaplan-Pavlovcic S, Ferluga D. Histologic and immunohistologic study and clinical presentation of ANCA-associated glomerulonephritis with correlation to ANCA antigen specificity. Am J Kidney Dis. 2003;41:539–49. https://doi.org/10.1053/ajkd.2003.50142 .
doi: 10.1053/ajkd.2003.50142
pubmed: 12612976
Malik SI, Idrees MK, Naseem K, Sadiq S, Raza SH, Ahmad FU. Pattern of biopsy-proven kidney diseases: experience of a teaching hospital in Bahawalpur. Pakistan Saudi J Kidney Dis Transpl. 2019;30:1144–50. https://doi.org/10.4103/1319-2442.270271 .
doi: 10.4103/1319-2442.270271
pubmed: 31696854
Navaratnarajah A, Sambasivan K, Cook TH, Pusey C, Roufosse C, Willicombe M. Predicting long-term renal and patient survival by clinicopathological features in elderly patients undergoing a renal biopsy in a UK cohort. Clin Kidney J. 2019;12:512–20. https://doi.org/10.1093/ckj/sfz006 .
doi: 10.1093/ckj/sfz006
pubmed: 31384442
pmcid: 6672059
Lin W, Chen M, Cui Z, Zhao MH. The immunopathological spectrum of crescentic glomerulonephritis: a survey of 106 patients in a single Chinese center. Nephron Clin Pract. 2010;116:65–74. https://doi.org/10.1159/000314665 .
doi: 10.1159/000314665